This week's Fierce Biotech is brought to you by Adaptive Biotechnologies. Trouble viewing? Click here.
Hi E, The most recent draft guidance from the U.S. Food and Drug Administration (FDA) on CAR T-cell development, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,” includes recommendations for tracking and monitoring CAR T therapy—from preclinical testing through clinical manufacturing and tracking patients for 15 years post-infusion utilizing T-cell receptor (TCR) sequencing. For those developing and producing CAR T therapies, it is important to know how to execute against this guidance.
Adaptive Immunosequencing, a next generation sequencing T-cell receptor assay, provides a quantitative end-to-end solution. It can help CAR T developers follow the draft guidance and understand critical biomarkers during all phases of development and commercialization.
Adaptive can help CAR T developers: Streamline the development and commercialization of CAR T therapies Quicken the path to market Mitigate safety concerns Reduce costs
Want to learn more? Download our white paper today to discover how Adaptive Immunosequencing can help your organization develop and monitor CAR T therapies that adhere to the FDA draft guidance.
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact [email protected] or call 202-824-5074.
